SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 674.95+3.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (2929)4/29/2020 7:54:39 PM
From: Miljenko Zuanic1 Recommendation

Recommended By
CuttingEdge Bio

   of 3557
 
That $68m was probably before safety problem emerge, analyst were projecting 200-240m, 1Q.
That is why REGN reacted so strongly.
For me, the problem is/was fast Beovu adaptation, based on 12w schedule options, while Eylea have *anecdotal* (it was proven) 16 w option from Bayer study!!!!! (actually, 5 injection per Y)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News